ERBB2 and breast carcinoma: Furthermore, VP inhibited the growth of the paclitaxel-resistant breast cancer cell line MDA-MB-231 (Li et al., 2019), and sensitized the HER-2 positive breast cancer cell line HCC1569 to lapatinib (Lin et al., 2015).